ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.896,50
-0,14%
S&P 500
5.066,17
0,95%
Dow Jones
38.237,07
0,88%
Euro vs US Dollar
1,07286
0,10%
Bitcoin
59.227,22
1,70%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) News

STRO Sutro Biopharma Inc

3,9995
0,2595 (6,94%)
Zuletzt aktualisiert: 20:49:27
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Sutro Biopharma Inc STRO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,2595 6,94% 3,9995 20:49:27
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,80 3,695 4,01 3,74
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202414:00GLOBESutro Biopharma Announces Initiation of Randomized Portion..
02.4.202412:18GLOBESutro Biopharma Announces Pricing of $75 Million..
25.3.202421:30GLOBESutro Biopharma Reports Full Year 2023 Financial Results,..
07.3.202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.3.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202422:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
13.2.202418:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12.2.202412:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09.2.202422:27EDGAR2Form 8-K - Current report
09.2.202422:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.2.202422:05GLOBESutro Biopharma to Participate in Upcoming Investor..
31.1.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202423:14EDGAR2Form 144 - Report of proposed sale of securities
08.1.202413:31EDGAR2Form 8-K - Current report
04.1.202422:05GLOBESutro Biopharma Highlights Potential Multi-Cancer..
14.12.202322:05GLOBESutro Biopharma to Host Investor Webcast Highlighting..
11.12.202322:05GLOBESutro Biopharma Announces New Positive Data from the..
04.12.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.12.202322:05GLOBESutro Biopharma to Participate in the JMP Securities..
27.11.202322:05EDGAR2Form 8-K - Current report
27.11.202322:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
22.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
21.11.202322:05EDGAR2Form 8-K - Current report
21.11.202322:05GLOBESutro Biopharma Promotes Jane Chung to President and Chief..
13.11.202323:18EDGAR2Form S-3 - Registration statement under Securities Act of..
13.11.202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:30EDGAR2Form 8-K - Current report
13.11.202322:30GLOBESutro Biopharma Reports Third Quarter 2023 Financial..
22.10.202310:25GLOBESutro Biopharma Announces Presentation of Data for..
16.10.202322:05GLOBESutro Demonstrates Meaningful ADC Innovation with Five..
04.10.202322:31EDGAR2Form 8-K - Current report
19.9.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.9.202322:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
19.9.202314:00GLOBESutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief..
30.8.202314:00GLOBESutro Biopharma to Participate in Upcoming Investor..
29.8.202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.8.202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.8.202322:46EDGAR2Form 144 - Report of proposed sale of securities
11.8.202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.8.202322:31EDGAR2Form 8-K - Current report
10.8.202322:30GLOBESutro Biopharma Reports Second Quarter 2023 Financial..
14.7.202300:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.6.202314:00GLOBESutro Biopharma and Blackstone Announce Royalty Financing..
03.6.202322:00GLOBESutro Biopharma Announces Oral Presentation at ASCO 2023..
31.5.202314:00GLOBESutro Biopharma to Participate in the Jefferies Healthcare..

Kürzlich von Ihnen besucht

NASDAQ
STRO
Sutro Biopharma
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten